Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "Australia"

206 News Found

Ministry of Ayush announces setting up of Academic Chair at Western Sydney University
News | November 23, 2022

Ministry of Ayush announces setting up of Academic Chair at Western Sydney University

It will undertake academic and collaborative research activities in Ayurveda, including herbal medicine and yoga, as well as design academic standards, short-term/medium-term courses, and educational guidelines


USFDA completes pre-approval inspection of BHL's Vadodara facility
Drug Approval | November 21, 2022

USFDA completes pre-approval inspection of BHL's Vadodara facility

The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited


Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
News | October 27, 2022

Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr

Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr


DKSH acquires two ear care brands
News | October 14, 2022

DKSH acquires two ear care brands

DKSH has signed an agreement to acquire two ear care brands from Noru Pharma for Australia, New Zealand, and selected markets in Asia.


AIIA signs MoU with AIST
Policy | October 09, 2022

AIIA signs MoU with AIST

The MoU will enable both countries to promote research collaboration and building capacities in the field of the Indian Ayurvedic system of traditional medicines


Cytel unlocks innovative clinical development expertise for APAC biopharma sector
Biotech | September 15, 2022

Cytel unlocks innovative clinical development expertise for APAC biopharma sector

Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.


Lupin receives Health Canada approval for Rymti
Drug Approval | September 14, 2022

Lupin receives Health Canada approval for Rymti

Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis


USFDA approves first treatment option for generalized pustular psoriasis flares in adults
Drug Approval | September 03, 2022

USFDA approves first treatment option for generalized pustular psoriasis flares in adults

Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares


Swissmedic approves Kapruvia with additional regulatory decisions expected in H2 2022
Drug Approval | August 20, 2022

Swissmedic approves Kapruvia with additional regulatory decisions expected in H2 2022

Therapy recently approved in Canada under the brand name KORSUVA


CureVac, GSK start Phase 1 clinical study of omicron-targeting COVID-19 vaccine candidate
Clinical Trials | August 19, 2022

CureVac, GSK start Phase 1 clinical study of omicron-targeting COVID-19 vaccine candidate

Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines